Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Bayer Schering Pharma Ag

Johns Hopkins University

Mario Lobell

Ulf Bömer

Hartmut Schirok

Alexandros Vakalopoulos

Klemens Lustig

Katja Zimmermann

Niels Lindner

Karl-Heinz Schlemmer

Walter Hubsch

Adrian Tersteegen

Markus Follmann

Walter Hübsch

Joachim Telser

Dieter Lang

Volkhart Min-Jian Li

Gerhard Siemeister

Pierre Wasnaire

Chengzhi Zhang

Jacques P Dumas

Hans Briem

Hans-Georg Lerchen

Barton W Phillips

Alexander Hillisch

Knut Eis

Nils Griebenow

Bernd Buchmann

Ulrich Lücking

Lars Bärfacker

Susanne Röhrig

Christoph Gerdes

Gan Wang

Martina Schäfer

Wendy Lee

Anja Buchmüller

Stefan Heitmeier

Joerg Keldenich

Qian Zhao

Shendong Yuan

Beatrix Stelte-Ludwig

Stephen J O'Connor

Yolanda Cancho Grande

Gaetan H Ladouceur

Kyle E Parcella

Tatiana Shelekhin

Hartmut Beck

Judith Günther

David Gunn

Xin Ma

Simone Greven

Zheng Liu

Stefan Golz

Jens Hoffmann

Simon Holton

Dirk Brohm

Nicole Teusch

Martin Michels

Sylvia Grünewald

Jürgen Klar

Marie-Pierre Collin

Verena Vöhringer

Frank Süβmeier

Karen Engel

Andreas Schall

Michael Böttger

Sven Wittrock

Michael Härter

Christoph Mahlert

Kirstin Petersen

Henrik Teller

Donald Bierer

Olaf Prien

Chetan Padmakar Darne

Julie A Dixon

Sandra Berndt

Carsten Terjung

Martina Victoria Schmidt

Kersten Matthias Gericke

Anette Sommer

Georges Von Degenfeld

Jason S Newcom

Dieter Zopf

Christiana I Iwuagwu

Susanne Greschat

Elisabeth Woltering

Cynthia Ann Berlinicke

Jennifer Burke

Julia Straβburger

Antje Kahnert

Herbert Himmel

Julia Strassburger

Hannah Jörißen

Derek Stuart Welsbie

Christiana Iwuagwu

Gaetan Ladouceur

Furahi Achebe

Shihong Ying

Hannah Jöriβen

Wenlang Fu

Kristen M Allegue

Juergen Klar

The invention relates to 5-({6-amino-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxopyridin-1(2H)-yl]-3-methylhexanoyl}amino)pyrazolo[1,5-a]pyridine-3-carboxamide to processes for its preparation, to its use for the treatment and/or prophylaxis of diseases and to its use for the preparation of medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and edemas, and also ophthalmic disorders, and its use to inhibit disturbing plasma kallikrein activity for the conduct of extracorporeal procedures and analytical assays.

Substituted oxopyridine derivative

The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

Substituted oxopyridine derivatives

The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

Substituted pyridobenzodiazepinone-derivatives and use thereof

The present application relates to novel antibody drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.

Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)

This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-fJ[1,2,4]triazin-4-amine derivatives having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases. 

Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer

This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases.

Substituted benzothienyl-pyrrolotriazines and uses thereof

The present invention relates to novel fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.

Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof

The present application relates to novel 1-phenyl-1H-imidazo[1,2-b]pyrazole derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular angiogenic disorders and hyperproliferative disorders, where neovascularization plays a role, such as, for example, neoplastic disorders and tumor disorders. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.

Substituted phenylimidazopyrazoles and their use

Disubstituted benzothienyl-pyrrolotriazines and uses thereof

This invention relates to novel 4-(indazol-5-yl)-4,7-dihydroisoxazolo[5,4-b]pyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.

Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof

This invention relates to novel 5-[(hydroxymethyl)aryl]-substituted pyrrolo[2,1-f][1,2,4]triazin-4-amines of formula (I), to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating angiogenesis-related disorders, in particular angiogenesis-related ocular disorders. 

Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors

The present invention relates to novel, fluoro-substituted 2-aryl-3,5-dicyano-4-(1H-indazol-5-yl)-6-methyl-1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly Cancer and other proliferative disorders.

Fluoro-substituted 2-aryl-3,5-dicyano-4-indazolyl-6-methyl-1,4-dihydropyridines and uses thereof

This invention relates to novel bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.

Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof

This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly cancer.

Substituted tricyclic compounds and methods of use thereof

This invention relates to compounds of Formula (I), wherein the variables are as disclosed in the specification, to pharmaceutical compositions containing them, to methods of making the compounds and pharmaceutical compositions, and to methods of using the compounds and pharmaceutical compositions for treating or preventing disorders, in particular cancer.

Tetrahydropyridothienopyrimidine compounds and methods of use thereof

Growing community of inventors

Wuppertal, Germany

Mario Lobell